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(DITORIAL COMMENT
-Wave and Non–Q-Wave
yocardial Infarctions
hrough the Eyes of Cardiac
agnetic Resonance Imaging*
ndrew E. Arai, MD, Glenn A. Hirsch, MD
ethesda, Maryland
t is worth contemplating how information from evolving
echnologies alters our understanding of established meth-
dologies. As we have redefined the very definitions of
yocardial infarction (MI) in the past several years (1), the
ardiology community has strived to unify our understand-
ngs of basic pathophysiology with sensible treatment algo-
ithms. For many clinicians, the diagnostic importance of
he Q-wave myocardial infarction (QWMI) and the non–
-wave myocardial infarction (NQWMI) have probably
een overshadowed by the more recent practice guidelines
entered on the presence or absence of acute ST-segment
levation (2). In this context, it is worth considering the
elative value of the Q-wave versus ST-segment classifica-
ions of MI to highlight important differences in our
pproaches to patients. It is also worth considering some
nsights about MI that have been derived from cardiac
agnetic resonance (CMR) over the last few years.
See page 554
In practice, the immediate evaluation and triage of
atients with possible or probable acute coronary syndrome
egins with a 12-lead electrocardiogram (ECG) to look for
T-segment elevation. ST-segment elevation in the appro-
riate clinical setting triggers percutaneous intervention, if
easible, or thrombolytic therapy if not contraindicated
2,3). Even before the use of high-sensitivity troponin
ssays, ST-segment elevation on an ECG had a relatively
oor sensitivity (50%) for acute MI (4). One might
onder why a test with such a low sensitivity plays such a
entral role in patient management when new tests with
uch low sensitivity would have trouble getting published.
he answer is in the high specificity of ST-segment
levation for acute MI, low cost, simplicity, and near-
niversal availability. The resulting high positive predictive
alue allows us to safely institute therapies that are either
xpensive, are labor intensive, or have undesirable potential
dverse effects. Furthermore, large infarcts are the most
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the National Heart, Lung, and Blood Institute, National Institutes of Health,aethesda, Maryland.ikely to demonstrate ST-segment elevation and are the
ost likely to benefit from emergency interventions.
The distinction between QWMI and NQWMI contin-
es to have clinical value because this ECG finding reflects
he underlying pathology (5). The CMR study by Moon et
l. (6) in the current issue of the Journal demonstrates that
-waves are indicative of larger MIs but are not particularly
seful in determining the transmural extent of infarction.
he authors graphically demonstrate that even the classifi-
ation of an infarct as transmural or subendocardial is overly
implistic. Moon et al. (6) found that 99% of patients with
WMI had a least a portion of that infarction in a
ubendocardial distribution, whereas 28% of patients with a
QWMI had regions of infarction that were transmural.
The NQWMIs have a better in-hospital prognosis, but
ong-term prognosis is similar or worse than QWMI. The
ntermediate- and long-term prognosis data for NQWMI
robably represent two determining factors. Early after
nfarction, the patient with a NQWMI is more likely to
ave residual viable but ischemic myocardium than the
atient with a QWMI (7) and is more vulnerable to
ecurrent infarction or ischemia. Late prognosis is probably
etermined by the consequences of having ischemic heart
isease.
What role do Q-waves play in our current clinical
lgorithms? The natural history of the Q-wave takes time to
evelop—often well after the important initial diagnostic
nd therapeutic interventions have taken place. Thus, the
-wave does not figure strongly in our acute-management
ecisions. Although early data from Thrombolysis in Myo-
ardial Infarction IIIB (8) and Veterans Affairs Non–Q-
ave Infarction Strategies in Hospital (9) trials did not
upport an early aggressive interventional approach to
QWMI, more recent clinical trials, such as the Treat
ngina With Aggrastat and Determine Cost of Therapy
ith an Invasive or Conservative Strategy (10) and Fragmin
nd Fast Revascularization During Instability in Coronary
rtery Disease Investigators II (11) trials, support the
odern invasive strategy of non–ST-segment elevation
cute coronary syndrome. In the latter studies, an invasive
trategy demonstrated improved mortality, reduced rates of
ecurrent infarction, improved symptoms, and lower read-
ission rates compared with a conservative strategy. This is
articularly true for the patient with non–ST-segment
levation MI, a group that most commonly has a NQWMI.
uring the chronic phase of the disease, the Q-wave
emains the most specific ECG finding for MI.
Many cardiologists wonder what impact CMR and other
ew technologies will have on the practice of cardiology.
any also question whether CMR is more than an aca-
emic or research tool. In short, CMR is a very powerful
echnique, particularly for characterization of patients with
schemic heart disease. Cine magnetic resonance imaging
MRI) methods provide exquisite views of cardiac anatomy
nd function (12). Even under the most difficult diagnostic
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ates of dobutamine stress testing, CMR is at least as
ensitive and specific as dobutamine stress echocardiography
or the detection of coronary artery disease (13,14), is
easible on a large scale at a few centers, and provides results
hat have prognostic significance (15).
Cardiac magnetic resonance viability techniques have
enerated high interest in the field and are ready for
idespread clinical dissemination. Searching the literature
ublished before 1999 will show a range of confusing and
ontradictory results. A major technical breakthrough
round 1999 greatly improved CMR imaging of MI (16).
his method has been validated in animal models of acute
nd chronic MI (17). The method is directly applicable to
umans and able to predict the recovery of regional con-
ractile function in patients with coronary artery disease
ased on the transmural extent of infarction (18). The
resence or absence of Q-waves should not be used to
etermine viability. Although techniques such as positron
mission tomography (PET), dobutamine echocardiogra-
hy, and thallium scans can evaluate viability clinically,
MR has the unique ability to define the transmural extent
f infarction.
Because there are many clinical tools available for imag-
ng viable myocardium, one might ask, “Why bother with
MR?” This can be answered simply by considering the
ollowing characteristics of CMR viability imaging: accu-
acy, resolution, and simplicity. Human studies have con-
rmed the accuracy of CMR by the strong correlation
etween CMR and PET (19). However, these authors note
hat 47% of CMR scans showing only subendocardial
nfarction were read as normal on the PET scan. Similarly,
agner et al. (20) reported that single photon emission
omputed tomography scans routinely miss subendocardial
nfarction in animals and in humans. The high image
esolution has allowed the detection of infarction associated
ith recognized side-branch occlusions during percutaneous
oronary interventions and the effects of distal embolization
21) and may explain why lower-resolution tests miss small
nfarctions. Using gadolinium-enhanced CMR, viability can
e assessed without a stress test, which facilitates its use in
he acutely ill patients.
The skeptic may wonder whether the tiny areas of MI
hat may be found have any clinical significance. Although
ong-term studies remain to be completed, the literature on
roponin indicates that even the smallest recognized MIs (1)
ave important prognostic significance (22). Because CMR
tudies can detect smaller infarcts than other imaging
odalities, one can extrapolate that prognostic studies will
ltimately demonstrate that CMR viability imaging carries
imilar prognostic value.
Clinicians also wonder about the general feasibility of
MR. Is it safe to perform a CMR scan on acutely ill
atients? Ultimately, the safety and feasibility of CMR is
oing to be determined by the degree of responsibility
ccepted by the physicians supervising the study. Thistatement is no different than quality assurance standards for
erforming stress testing, transesophageal echocardiogra-
hy, cardiac catheterization, and percutaneous coronary
nterventions. When performed by well-trained and consci-
ntious physicians, it is safe to do procedures that were
rankly contraindicated 20 to 30 years ago. As an indication
f feasibility, we were able to safely study patients with
ossible or probable acute coronary syndrome within 6 h of
resentation to a community hospital emergency depart-
ent and to achieve higher diagnostic accuracy than a
onventional clinical assessment (23).
What are the disadvantages of the CMR technique? The
reatest problems limiting widespread dissemination of this
echnology revolve around reimbursement issues, patient
ontraindications, physician education, rapidly changing
echnology, and control of MRI scanners. As of 2003,
atients with pacemakers, defibrillators, ferromagnetic brain
neurysm clips, and certain other medical devices should not
ndergo a CMR scan (24). Although the technology is
xpensive, MRI scanners can be profitable devices in the
reatment of neurological diseases and orthopedics, so it is
easonable to believe the systems could be profitable for
ardiovascular diseases, particularly in light of the wide
ange of cardiovascular applications and the large number of
atients requiring evaluation for ischemic heart disease.
ther barriers to the widespread implementation of CMR
nclude some significant training issues and the limited
umber of training centers. Many clinicians find MRI
hysics to be relatively complicated, and this is further
omplicated by rapid innovations and technical develop-
ents in the field. Finally, disappointing “turf” battles
emain between cardiologists and radiologists at many
enters.
In a time when medicine relies increasingly on high
echnology, it is reassuring to recognize the continued
ositive impact of simple and inexpensive tests such as the
CG. Electrocardiographic abnormalities associated with
I were first reported in 1920 (25). More than 80 years
ater, the widespread reliance of physicians on the ECG for
riage and diagnosis of patients helps put in perspective why
his invention warranted awarding a Nobel Prize to Willem
inthoven in 1924. Hopefully, CMR will continue to
evelop and provide useful diagnostic information for an
qually long history beyond the 2003 Nobel Prize awarded
o Paul Lauterbur and Sir Peter Mansfield for their discov-
ries concerning MRI.
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0, Room B1D416, MSC 1061, 10 Center Drive, Bethesda,
aryland 20892-1061. E-mail: araia@nih.gov.
EFERENCES
1. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial
infarction redefined—a consensus document of the Joint European
11
1
1
1
1
1
1
1
1
2
2
2
2
2
2
563JACC Vol. 44, No. 3, 2004 Arai and Hirsch
August 4, 2004:561–3 Editorial CommentSociety of Cardiology/American College of Cardiology Committee
for the redefinition of myocardial infarction. J Am Coll Cardiol
2000;36:959 –69.
2. Ryan TJ, Anderson JL, Antman EM, et al. ACC/AHA guidelines for
the management of patients with acute myocardial infarction. A report
of the American College of Cardiology/American Heart Association
Task Force on Practice Guidelines (Committee on Management of
Acute Myocardial Infarction). J Am Coll Cardiol 1996;28:1328–428.
3. Van de Werf F, Ardissino D, Betriu A, et al. Management of acute
myocardial infarction in patients presenting with ST-segment eleva-
tion. The Task Force on the Management of Acute Myocardial
Infarction of the European Society of Cardiology. Eur Heart J
2003;24:28–66.
4. Gibler WB, Lewis LM, Erb RE, et al. Early detection of acute
myocardial infarction in patients presenting with chest pain and
nondiagnostic ECGs: serial CK-MB sampling in the emergency
department. Ann Emerg Med 1990;19:1359–66.
5. Liebson PR, Klein LW. The non–Q-wave myocardial infarction
revisited: 10 years later. Prog Cardiovasc Dis 1997;39:399–444.
6. Moon JCC, Perez de Arenaza D, Elkington AG, et al. The pathologic
basis of Q-wave and non–Q-wave myocardial infarction: a cardiovas-
cular magnetic resonance study. J Am Coll Cardiol 2004;44:554–60.
7. Yang H, Pu M, Rodriguez D, et al. Ischemic and viable myocardium
in patients with non–Q-wave or Q-wave myocardial infarction and left
ventricular dysfunction: a clinical study using positron emission to-
mography, echocardiography, and electrocardiography. J Am Coll
Cardiol 2004;43:592–8.
8. Effects of tissue plasminogen activator and a comparison of early
invasive and conservative strategies in unstable angina and non–Q-
wave myocardial infarction. Results of the TIMI IIIB Trial. Throm-
bolysis in Myocardial Ischemia. Circulation 1994;89:1545–56.
9. Boden WE, O’Rourke RA, Crawford MH, et al. Outcomes in patients
with acute non–Q-wave myocardial infarction randomly assigned to an
invasive as compared with a conservative management strategy. Vet-
erans Affairs Non–Q-Wave Infarction Strategies in Hospital
(VANQWISH) Trial Investigators. N Engl J Med 1998;338:1785–92.
0. Cannon CP, Weintraub WS, Demopoulos LA, Robertson DH,
Gormley GJ, Braunwald E. Invasive versus conservative strategies in
unstable angina and non–Q-wave myocardial infarction following
treatment with tirofiban: rationale and study design of the interna-
tional TACTICS-TIMI 18 Trial. Treat Angina with Aggrastat and
determine Cost of Therapy with an Invasive or Conservative Strategy.
Thrombolysis In Myocardial Infarction. Am J Cardiol 1998;82:731–6.
1. Invasive compared with non-invasive treatment in unstable coronary-
artery disease: FRISC II prospective randomised multicentre study.
FRagmin and Fast Revascularisation during InStability in Coronary
artery disease Investigators. Lancet 1999;354:708–15.2. Barkhausen J, Ruehm SG, Goyen M, Buck T, Laub G, Debatin JF.
MR evaluation of ventricular function: true fast imaging with steady-
state precession versus fast low-angle shot cine MR imaging: feasibility
study. Radiology 2001;219:264–9.
3. Nagel E, Lehmkuhl HB, Bocksch W, et al. Noninvasive diagnosis of
ischemia-induced wall motion abnormalities with the use of high-dose
dobutamine stress MRI: comparison with dobutamine stress echocar-
diography. Circulation 1999;99:763–70.
4. Hundley WG, Hamilton CA, Thomas MS, et al. Utility of fast cine
magnetic resonance imaging and display for the detection of myocar-
dial ischemia in patients not well suited for second harmonic stress
echocardiography. Circulation 1999;100:1697–702.
5. Hundley WG, Morgan TM, Neagle CM, Hamilton CA, Rerkpat-
tanapipat P, Link KM. Magnetic resonance imaging determination of
cardiac prognosis. Circulation 2002;106:2328–33.
6. Simonetti OP, Kim RJ, Fieno DS, et al. An improved MR imaging
technique for the visualization of myocardial infarction. Radiology
2001;218:215–23.
7. Kim RJ, Fieno DS, Parrish TB, et al. Relationship of MRI delayed
contrast enhancement to irreversible injury, infarct age, and contractile
function. Circulation 1999;100:1992–2002.
8. Kim RJ, Wu E, Rafael A, et al. The use of contrast-enhanced
magnetic resonance imaging to identify reversible myocardial dysfunc-
tion. N Engl J Med 2000;343:1445–53.
9. Klein C, Nekolla SG, Bengel FM, et al. Assessment of myocardial
viability with contrast-enhanced magnetic resonance imaging: com-
parison with positron emission tomography. Circulation 2002;105:
162–7.
0. Wagner A, Mahrholdt H, Holly TA, et al. Contrast-enhanced MRI
and routine single photon emission computed tomography (SPECT)
perfusion imaging for detection of subendocardial myocardial infarcts:
an imaging study. Lancet 2003;361:374–9.
1. Ricciardi MJ, Wu E, Davidson CJ, et al. Visualization of discrete
microinfarction after percutaneous coronary intervention associated
with mild creatine kinase-MB elevation. Circulation 2001;103:
2780–3.
2. Antman EM, Grudzien C, Mitchell RN, Sacks DB. Detection of
unsuspected myocardial necrosis by rapid bedside assay for cardiac
troponin T. Am Heart J 1997;133:596–8.
3. Kwong RY, Schussheim AE, Rekhraj S, et al. Detecting acute
coronary syndrome in the emergency department with cardiac mag-
netic resonance imaging. Circulation 2003;107:531–7.
4. Shellock FG. Reference Manual for Magnetic Resonance Safety,
Implants, and Devices. Los Angeles, CA: Biomedical Research Pub-
lishing Group, 2004.
5. Pardee HEB. An electrocardiographic sign of coronary artery obstruc-
tion. Arch Intern Med 1920;26:244–57.
